Royalty Pharma plc


SKU: RPRX Category:


This is our first report on Royalty Pharma Plc. The company has been performing reasonably well as it continues to execute its strategy as a prominent funder of modernization in life science. Royalty Pharma has maintained an active and robust deal pipeline reflecting strong growth in the demand for the new royalty-based funding solutions. The company has seen significant growth contributions from the Biohaven payments, Promacta, Evrysdi, and Cabometyx. Royalty Pharma has recently announced that it has acquired royalty interest in Gavreto from Blueprint Medicines for up to $340 million. In the quarter, the growth drivers were the innovative royalty on Tremfya, Tysabri, and the cystic fibrosis franchise. Additional royalty interests have been acquired by Royalty Pharma in Orladeyo and BCX9930 from BioCryst Pharmaceuticals. The management also announced announced that it has acquired the royal interest of Dicerna Pharmaceuticals in Oxlumo for $240 million. In the quarter, 15% growth in the adjusted cash receipts has been delivered. The company continues to maintain substantial financial firepower. We provide a ‘Hold’ rating on the stock of Royalty Pharma plc.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!